Global Malignant Mesothelioma Therapeutics Market 2019-2023 | 7% CAGR Projection Over the Next Five Years | Technavio

Technavio has announced its latest market research report titled global malignant mesothelioma therapeutics market 2019-2023. (Graphic: Business Wire)

LONDON--()--The global malignant mesothelioma therapeutics market is expected to post a CAGR of close to 7% during the period 2019-2023, according to the latest market research report by Technavio.

A key factor driving the growth of the global malignant mesothelioma therapeutics market size is the increasing use of asbestos for commercial purposes. Exposure to asbestos is the primary risk factor for malignant mesothelioma. Over the years, the use of asbestos has increased significantly in various applications such as machines, building materials, and transport vehicles. Thus, the extensive use of asbestos for commercial purposes will drive the global malignant mesothelioma therapeutics market during the forecast period.

As per Technavio, the increasing awareness of malignant mesothelioma will have a positive impact on the market and contribute to its growth significantly over the forecast period. This global malignant mesothelioma therapeutics market 2019-2023 research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global Malignant Mesothelioma Therapeutics Market: Increasing Awareness of Malignant Mesothelioma

Over the years, the prevalence of malignant mesothelioma has been increasing at a significant rate across the world. This has led to a need for awareness initiatives to diagnose and treat the disease at the early stages. Therefore, several non-profit foundations and government authorities are taking initiatives to promote awareness about malignant mesothelioma among the population. The growing awareness will increase the number of patients availing the treatment, which will positively influence the malignant mesothelioma therapeutics market during the forecast period.

“Apart from the increasing awareness of malignant mesothelioma, other factors such as the development of novel therapies, and the availability of reimbursement policies for chemotherapy will have a significant impact on the malignant mesothelioma therapeutics market growth during the forecast period,” says a senior analyst at Technavio.

Global Malignant Mesothelioma Therapeutics Market: Segmentation Analysis

This market research report segments the global malignant mesothelioma therapeutics market by product (chemotherapy, and other therapeutics) and geographic regions (North America, Europe, Asia, and ROW).

The North American region led the malignant mesothelioma therapeutics market in 2018, followed by Europe, Asia, and ROW respectively. The malignant mesothelioma therapeutics market report identifies, special regulatory designations, and the high adoption of the drug ALIMTA as factors that will further fuel the growth of the market in North America over the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Release Summary

The global malignant mesothelioma therapeutics market is expected to post a CAGR of close to 7% during 2019-2023, according to Technavio.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com